Araclon Biotech, a Grifols company, presented the results of its clinical validation study of ABtest-MS in populations with mild cognitive impairment, and of its ABvac40 vaccine regarding its impact on the progression of Alzheimer’s disease (AD) and Cerebral Amyloid Angiopathy (CAA) at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2025).
This event brought together experts and leaders in health, neuroscience, and biotechnology in Vienna to discuss the latest advances in neurodegenerative diseases such as AD and Parkinson’s, as well as in their diagnosis and treatment.
The results presented show that the ABtest-MS diagnostic test can reduce the need for invasive procedures by 70%, while maintaining high diagnostic accuracy. Its potential to facilitate the early identification of candidates for disease-modifying therapies—such as passive immunotherapies with anti-amyloid monoclonal antibodies—was also highlighted. Araclon Biotech is currently continuing validation of the test in new cohorts to strengthen its application in clinical practice.
Progress was also shared regarding ABvac40, an active immunotherapy targeting the amyloid β40 peptide for the treatment of AD and CAA. In its phase 2 clinical trial, ABvac40 confirmed its safety and a strong immune response in patients with mild cognitive impairment or very mild AD. Unlike other monoclonal antibody treatments, ABvac40 showed a lower incidence of amyloid-related imaging abnormalities (ARIA). In addition, the results indicated slower progression of CAA in patients treated with the vaccine compared to the placebo group, supporting its mechanism of action and highlighting ABvac40 as a promising therapeutic alternative with the potential to reduce risks associated with other passive immunotherapies.
These findings reinforce the potential of both strategies—early diagnosis and treatment—contributing to the advancement of new therapeutic solutions against AD.
